ADVERSE O
REACTIONS O
Spasticity O
of O
Spinal O
Cord O
Origin O
Clinical O
Studies O
Commonly O
Observed O
in O
Patients O
with O
Spasticity O
of O
Spinal O
Origin O
In O
pre- O
and O
post- O
marketing O
clinical O
trials O
, O
the O
most O
commonly O
observed O
adverse O
events O
associated O
with O
use O
of O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
which O
were O
not O
seen O
at O
an O
equivalent O
incidence O
among O
placebo-treated O
patients O
were O
: O
somnolence B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
convulsions B-OSE_Labeled_AE
and O
hypotonia B-OSE_Labeled_AE
. O

Associated O
with O
Discontinuation O
of O
Treatment O
8/474 O
patients O
with O
spasticity B-Not_AE_Candidate
of I-Not_AE_Candidate
spinal I-Not_AE_Candidate
cord I-Not_AE_Candidate
origin I-Not_AE_Candidate
receiving O
long O
term O
infusion O
of O
LIORESAL O
INTRATHECAL O
in O
pre- O
and O
post- O
marketing O
clinical O
studies O
in O
the O
U O
. O
S O
. O
discontinued O
treatment O
due O
to O
adverse O
events O
. O

These O
include O
: O
pump B-OSE_Labeled_AE
pocket I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
3 O
) O
, O
meningitis B-OSE_Labeled_AE
( O
2 O
) O
, O
wound B-OSE_Labeled_AE
dehiscence I-OSE_Labeled_AE
( O
1 O
) O
, O
gynecological B-OSE_Labeled_AE
fibroids I-OSE_Labeled_AE
( O
1 O
) O
and O
pump B-OSE_Labeled_AE
overpressurization I-OSE_Labeled_AE
( O
1 O
) O
with O
unknown O
, O
if O
any O
, O
sequela O
. O

Eleven O
patients O
who O
developed O
coma B-NonOSE_AE
secondary O
to O
overdose B-NonOSE_AE
had O
their O
treatment O
temporarily O
suspended O
, O
but O
all O
were O
subsequently O
re-started O
and O
were O
not O
, O
therefore O
, O
considered O
to O
be O
true O
discontinuations O
. O

Fatalities B-NonOSE_AE
See O
Warnings O
. O

Incidence O
in O
Controlled O
Trials O
Experience O
with O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
obtained O
in O
parallel O
, O
placebo-controlled O
, O
randomized O
studies O
provides O
only O
a O
limited O
basis O
for O
estimating O
the O
incidence O
of O
adverse O
events O
because O
the O
studies O
were O
of O
very O
brief O
duration O
( O
up O
to O
three O
days O
of O
infusion O
) O
and O
involved O
only O
a O
total O
of O
63 O
patients O
. O

The O
following O
events O
occurred O
among O
the O
31 O
patients O
receiving O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
in O
two O
randomized O
, O
placebo-controlled O
trials O
: O
hypotension B-OSE_Labeled_AE
( O
2 O
) O
, O
dizziness B-OSE_Labeled_AE
( O
2 O
) O
, O
headache B-OSE_Labeled_AE
( O
2 O
) O
, O
dyspnea B-OSE_Labeled_AE
( O
1 O
) O
. O

No O
adverse O
events O
were O
reported O
among O
the O
32 O
patients O
receiving O
placebo O
in O
these O
studies O
. O

Events O
Observed O
during O
the O
Pre- O
and O
Post-marketing O
Evaluation O
of O
LIORESAL O
INTRATHECAL O
Adverse O
events O
associated O
with O
the O
use O
of O
LIORESAL O
INTRATHECAL O
reflect O
experience O
gained O
with O
576 O
patients O
followed O
prospectively O
in O
the O
United O
States O
. O

They O
received O
LIORESAL O
INTRATHECAL O
for O
periods O
of O
one O
day O
( O
screening O
) O
( O
N O
= O
576 O
) O
to O
over O
eight O
years O
( O
maintenance O
) O
( O
N O
= O
10 O
) O
. O

The O
usual O
screening O
bolus O
dose O
administered O
prior O
to O
pump O
implantation O
in O
these O
studies O
was O
typically O
50 O
mcg O
. O

The O
maintenance O
dose O
ranged O
from O
12 O
mcg O
to O
2003 O
mcg O
per O
day O
. O

Because O
of O
the O
open O
, O
uncontrolled O
nature O
of O
the O
experience O
, O
a O
causal O
linkage O
between O
events O
observed O
and O
the O
administration O
of O
LIORESAL O
INTRATHECAL O
can O
not O
be O
reliably O
assessed O
in O
many O
cases O
and O
many O
of O
the O
adverse O
events O
reported O
are O
known O
to O
occur O
in O
association O
with O
the O
underlying O
conditions O
being O
treated O
. O

Nonetheless O
, O
many O
of O
the O
more O
commonly O
reported O
reactions- O
hypotonia B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
/ O
vomiting B-OSE_Labeled_AE
and O
headache B-OSE_Labeled_AE
- I-OSE_Labeled_AE
appear O
clearly O
drug-related O
. O

Adverse O
experiences O
reported O
during O
all O
U.S O
. O
studies O
( O
both O
controlled O
and O
uncontrolled O
) O
are O
shown O
in O
the O
following O
table O
. O

Eight O
of O
474 O
patients O
who O
received O
chronic O
infusion O
via O
implanted O
pumps O
had O
adverse O
experiences O
which O
led O
to O
a O
discontinuation O
of O
long O
term O
treatment O
in O
the O
pre- O
and O
post-marketing O
studies O
. O

INCIDENCE O
OF O
MOST O
FREQUENT O
( O
> O
=1 O
% O
) O
ADVERSE O
EVENTS O
IN O
PATIENTS O
WITH O
SPASTICITY O
OF O
SPINAL O
ORIGIN O
IN O
PROSPECTIVELY O
MONITORED O
CLINICAL O
TRIALS O
Percent O
of O
Patients O
Reporting O
Events O
N O
= O
576Screening O
[ O
note O
: O
Following O
administration O
of O
test O
bolus O
] O
Percent O
N O
= O
474Titration O
[ O
note O
: O
Two O
month O
period O
following O
implant O
] O
Percent O
N O
= O
430Maintenance O
[ O
note O
: O
Beyond O
two O
months O
following O
implant O
] O
Percent O
Adverse O
Event O
N= O
total O
number O
of O
patients O
entering O
each O
period O
% O
= O
% O
of O
patients O
evaluated O
Hypotonia B-OSE_Labeled_AE
5.4 O
13.5 O
25.3 O
Somnolence B-OSE_Labeled_AE
5.7 O
5.9 O
20.9 O
Dizziness B-OSE_Labeled_AE
1.7 O
1.9 O
7.9 O
Paresthesia B-OSE_Labeled_AE
2.4 O
2.1 O
6.7 O
Nausea B-OSE_Labeled_AE
and O
Vomiting B-OSE_Labeled_AE
1.6 O
2.3 O
5.6 O
Headache B-OSE_Labeled_AE
1.6 O
2.5 O
5.1 O
Constipation B-OSE_Labeled_AE
0.2 O
1.5 O
5.1 O
Convulsion B-OSE_Labeled_AE
0.5 O
1.3 O
4.7 O
Urinary B-OSE_Labeled_AE
Retention I-OSE_Labeled_AE
0.7 O
1.7 O
1.9 O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
0.2 O
0.4 O
3.3 O
Accidental B-OSE_Labeled_AE
Injury I-OSE_Labeled_AE
0.0 O
0.2 O
3.5 O
Asthenia B-OSE_Labeled_AE
0.7 O
1.3 O
1.4 O
Confusion B-OSE_Labeled_AE
0.5 O
0.6 O
2.3 O
Death B-NonOSE_AE
0.2 O
0.4 O
3.0 O
Pain B-OSE_Labeled_AE
0.0 O
0.6 O
3.0 O
Speech B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
0.0 O
0.2 O
3.5 O
Hypotension B-OSE_Labeled_AE
1.0 O
0.2 O
1.9 O
Ambylopia B-OSE_Labeled_AE
0.5 O
0.2 O
2.3 O
Diarrhea B-OSE_Labeled_AE
0.0 O
0.8 O
2.3 O
Hypoventilation B-OSE_Labeled_AE
0.2 O
0.8 O
2.1 O
Coma B-OSE_Labeled_AE
0.0 O
1.5 O
0.9 O
Impotence B-OSE_Labeled_AE
0.2 O
0.4 O
1.6 O
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
0.0 O
0.0 O
2.3 O
Urinary B-OSE_Labeled_AE
Incontinence I-OSE_Labeled_AE
0.0 O
0.8 O
1.4 O
Insomnia B-OSE_Labeled_AE
0.0 O
0.4 O
1.6 O
Anxiety B-OSE_Labeled_AE
0.2 O
0.4 O
0.9 O
Depression B-OSE_Labeled_AE
0.0 O
0.0 O
1.6 O
Dyspnea B-OSE_Labeled_AE
0.3 O
0.0 O
1.2 O
Fever B-OSE_Labeled_AE
0.5 O
0.2 O
0.7 O
Pneumonia B-OSE_Labeled_AE
0.2 O
0.2 O
1.2 O
Urinary B-OSE_Labeled_AE
Frequency I-OSE_Labeled_AE
0.0 O
0.6 O
0.9 O
Urticaria B-OSE_Labeled_AE
0.2 O
0.2 O
1.2 O
Anorexia B-OSE_Labeled_AE
0.0 O
0.4 O
0.9 O
Diplopia B-OSE_Labeled_AE
0.0 O
0.4 O
0.9 O
Dysautonomia B-OSE_Labeled_AE
0.2 O
0.2 O
0.9 O
Hallucinations B-OSE_Labeled_AE
0.3 O
0.4 O
0.5 O
Hypertension B-OSE_Labeled_AE
0.2 O
0.6 O
0.5 O
In O
addition O
to O
the O
more O
common O
( O
1 O
% O
or O
more O
) O
adverse O
events O
reported O
in O
the O
prospectively O
followed O
576 O
domestic O
patients O
in O
pre- O
and O
post-marketing O
studies O
, O
experience O
from O
an O
additional O
194 O
patients O
exposed O
to O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
from O
foreign O
studies O
has O
been O
reported O
. O

The O
following O
adverse O
events O
, O
not O
described O
in O
the O
table O
, O
and O
arranged O
in O
decreasing O
order O
of O
frequency O
, O
and O
classified O
by O
body O
system O
, O
were O
reported O
: O
Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
Abnormal B-OSE_Labeled_AE
gait I-OSE_Labeled_AE
, O
thinking B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
twitching B-OSE_Labeled_AE
, O
vasodilitation B-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
nystagmus B-OSE_Labeled_AE
, O
personality B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
psychotic B-OSE_Labeled_AE
depression I-OSE_Labeled_AE
, O
cerebral B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
emotional B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
euphoria B-OSE_Labeled_AE
, O
hypertonia B-OSE_Labeled_AE
, O
ileus B-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
dependence I-OSE_Labeled_AE
, O
incoordination B-OSE_Labeled_AE
, O
paranoid B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
and O
ptosis B-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
System I-NonOSE_AE
: O
Flatulence B-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
and O
gastroenteritis B-OSE_Labeled_AE
. O

Cardiovascular B-NonOSE_AE
: O
Postural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
, O
palpitations B-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
arrhythmia B-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
, O
deep B-OSE_Labeled_AE
thrombophlebitis I-OSE_Labeled_AE
, O
pallor B-OSE_Labeled_AE
and O
tachycardia B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
: O
Respiratory B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
aspiration B-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
, O
hyperventilation B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolus I-OSE_Labeled_AE
and O
rhinitis B-OSE_Labeled_AE
. O

Urogenital B-NonOSE_AE
: O
Hematuria B-OSE_Labeled_AE
and O
kidney B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
Alopecia B-OSE_Labeled_AE
and O
sweating B-OSE_Labeled_AE
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
albuminuria B-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
and O
hyperglycemia B-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
Abnormal B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
abnormality B-OSE_Labeled_AE
of I-OSE_Labeled_AE
accommodation I-OSE_Labeled_AE
, O
photophobia B-OSE_Labeled_AE
, O
taste B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
and O
tinnitus B-OSE_Labeled_AE
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
Suicide B-OSE_Labeled_AE
, O
lack B-OSE_Labeled_AE
of I-OSE_Labeled_AE
drug I-OSE_Labeled_AE
effect I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
hypothermia B-OSE_Labeled_AE
, O
neck B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
face B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
flu B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
and O
overdose B-OSE_Labeled_AE
. O

Hemic B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
: O
Anemia B-OSE_Labeled_AE
. O

Spasticity O
of O
Cerebral O
Origin O
Clinical O
Studies O
Commonly O
Observed O
In O
pre-marketing O
clinical O
trials O
, O
the O
most O
commonly O
observed O
adverse O
events O
associated O
with O
use O
of O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
which O
were O
not O
seen O
at O
an O
equivalent O
incidence O
among O
placebo-treated O
patients O
included O
: O
agitation B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
leukocytosis B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
and O
hypotonia B-OSE_Labeled_AE
. O

Associated O
with O
Discontinuation O
of O
Treatment O
Nine O
of O
211 O
patients O
receiving O
LIORESAL O
INTRATHECAL O
in O
pre-marketing O
clinical O
studies O
in O
the O
U.S O
. O
discontinued O
long O
term O
infusion O
due O
to O
adverse O
events O
associated O
with O
intrathecal O
therapy O
. O

The O
nine O
adverse O
events O
leading O
to O
discontinuation O
were O
: O
infection B-OSE_Labeled_AE
( O
3 O
) O
, O
CSF B-OSE_Labeled_AE
leaks I-OSE_Labeled_AE
( O
2 O
) O
, O
meningitis B-OSE_Labeled_AE
( O
2 O
) O
, O
drainage B-OSE_Labeled_AE
( O
1 O
) O
, O
and O
unmanageable B-OSE_Labeled_AE
trunk I-OSE_Labeled_AE
control I-OSE_Labeled_AE
( O
1 O
) O
. O

Fatalities B-NonOSE_AE
Three O
deaths B-NonOSE_AE
, O
none O
of O
which O
were O
attributed O
to O
LIORESAL O
INTRATHECAL O
, O
were O
reported O
in O
patients O
in O
clinical O
trials O
involving O
patients O
with O
spasticity B-Not_AE_Candidate
of I-Not_AE_Candidate
cerebral I-Not_AE_Candidate
origin I-Not_AE_Candidate
. O

See O
Warnings O
on O
other O
deaths B-NonOSE_AE
reported O
in O
spinal B-Not_AE_Candidate
spasticity I-Not_AE_Candidate
patients O
. O

Incidence O
in O
Controlled O
Trials O
Experience O
with O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
obtained O
in O
parallel O
, O
placebo-controlled O
, O
randomized O
studies O
provides O
only O
a O
limited O
basis O
for O
estimating O
the O
incidence O
of O
adverse O
events O
because O
the O
studies O
involved O
a O
total O
of O
62 O
patients O
exposed O
to O
a O
single O
50 O
mcg O
intrathecal O
bolus O
. O

The O
following O
events O
occurred O
among O
the O
62 O
patients O
receiving O
LIORESAL O
INTRATHECAL O
in O
two O
randomized O
, O
placebo-controlled O
trials O
involving O
cerebral B-Not_AE_Candidate
palsy I-Not_AE_Candidate
and O
head B-Not_AE_Candidate
injury I-Not_AE_Candidate
patients O
, O
respectively O
: O
agitation B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
leukocytosis B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
nystagmus B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
and O
hypotonia B-OSE_Labeled_AE
. O

Events O
Observed O
during O
the O
Pre-marketing O
Evaluation O
of O
LIORESAL O
INTRATHECAL O
Adverse O
events O
associated O
with O
the O
use O
of O
LIORESAL O
INTRATHECAL O
reflect O
experience O
gained O
with O
a O
total O
of O
211 O
U O
. O
S O
. O
patients O
with O
spasticity B-Not_AE_Candidate
of I-Not_AE_Candidate
cerebral I-Not_AE_Candidate
origin I-Not_AE_Candidate
, O
of O
whom O
112 O
were O
pediatric O
patients O
( O
under O
age O
16 O
at O
enrollment O
) O
. O

They O
received O
LIORESAL O
INTRATHECAL O
for O
periods O
of O
one O
day O
( O
screening O
) O
( O
N= O
211 O
) O
to O
84 O
months O
( O
maintenance O
) O
( O
N= O
1 O
) O
. O

The O
usual O
screening O
bolus O
dose O
administered O
prior O
to O
pump O
implantation O
in O
these O
studies O
was O
50-75 O
mcg O
. O

The O
maintenance O
dose O
ranged O
from O
22 O
mcg O
to O
1400 O
mcg O
per O
day O
. O

Doses O
used O
in O
this O
patient O
population O
for O
long O
term O
infusion O
are O
generally O
lower O
than O
those O
required O
for O
patients O
with O
spasticity B-Not_AE_Candidate
of I-Not_AE_Candidate
spinal I-Not_AE_Candidate
cord I-Not_AE_Candidate
origin I-Not_AE_Candidate
. O

Because O
of O
the O
open O
, O
uncontrolled O
nature O
of O
the O
experience O
, O
a O
causal O
linkage O
between O
events O
observed O
and O
the O
administration O
of O
LIORESAL O
INTRATHECAL O
can O
not O
be O
reliably O
assessed O
in O
many O
cases O
. O

Nonetheless O
, O
many O
of O
the O
more O
commonly O
reported O
reactions- O
somnolence B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
hypotonia B-OSE_Labeled_AE
and O
coma B-OSE_Labeled_AE
- I-OSE_Labeled_AE
appear O
clearly O
drug-related O
. O

The O
most O
frequent O
( O
> O
=1 O
% O
) O
adverse O
events O
reported O
during O
all O
clinical O
trials O
are O
shown O
in O
the O
following O
table O
. O

Nine O
patients O
discontinued O
long O
term O
treatment O
due O
to O
adverse O
events O
. O

INCIDENCE O
OF O
MOST O
FREQUENT O
( O
> O
= O
1 O
% O
) O
ADVERSE O
EVENTS O
IN O
PATIENTS O
WITH O
SPASTICITY O
OF O
CEREBRAL O
ORIGIN O
IN O
PROSPECTIVELY O
MONITORED O
CLINICAL O
TRIALS O
Percent O
of O
Patients O
Reporting O
Events O
N O
= O
211Screening O
[ O
note O
: O
Following O
administration O
of O
test O
bolus O
] O
Percent O
N O
= O
153Titration O
[ O
note O
: O
Two O
month O
period O
following O
implant O
] O
Percent O
N O
= O
150Maintenance O
[ O
note O
: O
Beyond O
two O
months O
following O
implant O
] O
Percent O
Adverse O
Event O
N= O
Total O
number O
of O
patients O
entering O
each O
period O
. O

211 O
patients O
received O
drug O
; O
( O
1 O
of O
212 O
) O
received O
placebo O
only O
. O

Hypotonia B-OSE_Labeled_AE
2.4 O
14.4 O
34.7 O
Somnolence B-OSE_Labeled_AE
7.6 O
10.5 O
18.7 O
Headache B-OSE_Labeled_AE
6.6 O
7.8 O
10.7 O
Nausea B-OSE_Labeled_AE
and O
Vomiting B-OSE_Labeled_AE
6.6 O
10.5 O
4.0 O
Vomiting B-OSE_Labeled_AE
6.2 O
8.5 O
4.0 O
Urinary B-OSE_Labeled_AE
Retention I-OSE_Labeled_AE
0.9 O
6.5 O
8.0 O
Convulsion B-OSE_Labeled_AE
0.9 O
3.3 O
10.0 O
Dizziness B-OSE_Labeled_AE
2.4 O
2.6 O
8.0 O
Nausea B-OSE_Labeled_AE
1.4 O
3.3 O
7.3 O
Hypoventilation B-OSE_Labeled_AE
1.4 O
1.3 O
4.0 O
Hypertonia B-OSE_Labeled_AE
0.0 O
0.7 O
6.0 O
Paresthesia B-OSE_Labeled_AE
1.9 O
0.7 O
3.3 O
Hypotension B-OSE_Labeled_AE
1.9 O
0.7 O
2.0 O
Increased B-OSE_Labeled_AE
Salivation I-OSE_Labeled_AE
0.0 O
2.6 O
2.7 O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
0.9 O
0.7 O
2.0 O
Constipation B-OSE_Labeled_AE
0.5 O
1.3 O
2.0 O
Pain B-OSE_Labeled_AE
0.0 O
0.0 O
4.0 O
Pruritus B-OSE_Labeled_AE
0.0 O
0.0 O
4.0 O
Diarrhea B-OSE_Labeled_AE
0.5 O
0.7 O
2.0 O
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
0.0 O
0.0 O
3.3 O
Thinking B-OSE_Labeled_AE
Abnormal I-OSE_Labeled_AE
0.5 O
1.3 O
0.7 O
Agitation B-OSE_Labeled_AE
0.5 O
0.0 O
1.3 O
Asthenia B-OSE_Labeled_AE
0.0 O
0.0 O
2.0 O
Chills B-OSE_Labeled_AE
0.5 O
0.0 O
1.3 O
Coma B-OSE_Labeled_AE
0.5 O
0.0 O
1.3 O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
0.5 O
0.0 O
1.3 O
Pneumonia B-OSE_Labeled_AE
0.0 O
0.0 O
2.0 O
Speech B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
0.5 O
0.7 O
0.7 O
Tremor B-OSE_Labeled_AE
0.5 O
0.0 O
1.3 O
Urinary B-OSE_Labeled_AE
Incontinence I-OSE_Labeled_AE
0.0 O
0.0 O
2.0 O
Urination B-OSE_Labeled_AE
Impaired I-OSE_Labeled_AE
0.0 O
0.0 O
2.0 O
The O
more O
common O
( O
1 O
% O
or O
more O
) O
adverse O
events O
reported O
in O
the O
prospectively O
followed O
211 O
patients O
exposed O
to O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
have O
been O
reported O
. O

In O
the O
total O
cohort O
, O
the O
following O
adverse O
events O
, O
not O
described O
in O
the O
table O
, O
and O
arranged O
in O
decreasing O
order O
of O
frequency O
, O
and O
classified O
by O
body O
system O
, O
were O
reported O
: O
Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
Akathisia B-OSE_Labeled_AE
, O
ataxia B-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
opisthotonos B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
hysteria B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
nystagmus B-OSE_Labeled_AE
, O
personality B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
reflexes B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
and O
vasodilitation B-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
System I-NonOSE_AE
: O
Dysphagia B-OSE_Labeled_AE
, O
fecal B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
and O
tongue B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
. O

Cardiovascular B-NonOSE_AE
: O
Bradycardia B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
: O
Apnea B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
and O
hyperventilation B-OSE_Labeled_AE
. O

Urogenital B-NonOSE_AE
: O
Abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
, O
kidney B-OSE_Labeled_AE
calculus I-OSE_Labeled_AE
, O
oliguria B-OSE_Labeled_AE
and O
vaginitis B-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
Rash B-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
, O
contact B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
and O
skin B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
Abnormality B-OSE_Labeled_AE
of I-OSE_Labeled_AE
accommodation I-OSE_Labeled_AE
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
Death B-NonOSE_AE
, O
fever B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
carcinoma B-OSE_Labeled_AE
, O
malaise B-OSE_Labeled_AE
and O
hypothermia B-OSE_Labeled_AE
. O

Hemic B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
: O
Leukocytosis B-OSE_Labeled_AE
and O
petechial B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
. O

Postmarketing O
Experience O
The O
following O
adverse O
events O
have O
been O
reported O
during O
post-approval O
use O
of O
LIORESAL O
INTRATHECAL O
. O

Because O
these O
events O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
possible O
to O
reliably O
estimate O
their O
frequency O
. O

Musculoskeletal O
The O
onset O
of O
scoliosis B-OSE_Labeled_AE
or O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
a I-OSE_Labeled_AE
pre I-OSE_Labeled_AE
- I-OSE_Labeled_AE
existing I-OSE_Labeled_AE
scoliosis I-OSE_Labeled_AE
has O
been O
reported O
. O

Urogenital O
Sexual B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
in O
men O
and O
women O
, O
including O
decreased B-OSE_Labeled_AE
libido I-OSE_Labeled_AE
and O
orgasm B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
have O
been O
reported O
. O

Erectile B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
in O
men O
has O
also O
been O
reported O
. O

Priapism B-NonOSE_AE
has O
been O
reported O
following O
baclofen O
withdrawal B-NonOSE_AE
. O

